Insider Transactions in Q1 2021 at Artivion, Inc. (AORT)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 16
2021
|
Marshall S. Stanton SVP, Clinical & MD Affair |
BUY
Grant, award, or other acquisition
|
Direct |
8,511
+47.23%
|
-
|
|
Mar 12
2021
|
Scott B Capps VP, Clinical Research |
SELL
Payment of exercise price or tax liability
|
Direct |
1,393
-0.45%
|
$34,825
$25.05 P/Share
|
|
Mar 12
2021
|
John E Davis Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,236
-1.38%
|
$55,900
$25.05 P/Share
|
|
Mar 12
2021
|
Jean F Holloway SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,682
-1.5%
|
$67,050
$25.05 P/Share
|
|
Mar 12
2021
|
Amy Horton VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,739
-0.96%
|
$43,475
$25.05 P/Share
|
|
Mar 12
2021
|
David Ashley Lee Executive VP, COO & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,074
-0.52%
|
$76,850
$25.05 P/Share
|
|
Mar 12
2021
|
James P Mackin President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,766
-2.48%
|
$394,150
$25.05 P/Share
|
|
Mar 12
2021
|
Dennis B Maier SVP, Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,385
-3.13%
|
$34,625
$25.05 P/Share
|
|
Mar 10
2021
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
1,693
-1.85%
|
$42,325
$25.28 P/Share
|
|
Mar 08
2021
|
Franz Peter Barthold VP, Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
76
-0.62%
|
$1,824
$24.3 P/Share
|
|
Mar 05
2021
|
Franz Peter Barthold VP, Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
103
-0.84%
|
$2,472
$24.44 P/Share
|
|
Mar 05
2021
|
Scott B Capps VP, Clinical Research |
SELL
Payment of exercise price or tax liability
|
Direct |
205
-0.13%
|
$4,920
$24.44 P/Share
|
|
Mar 05
2021
|
John E Davis Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
315
-0.39%
|
$7,560
$24.44 P/Share
|
|
Mar 05
2021
|
Jean F Holloway SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
299
-0.33%
|
$7,176
$24.44 P/Share
|
|
Mar 05
2021
|
Amy Horton VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
226
-0.25%
|
$5,424
$24.44 P/Share
|
|
Mar 05
2021
|
David Ashley Lee Executive VP, COO & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
359
-0.12%
|
$8,616
$24.44 P/Share
|
|
Mar 05
2021
|
James P Mackin President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,487
-0.46%
|
$35,688
$24.44 P/Share
|
|
Mar 05
2021
|
Dennis B Maier SVP, Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
205
-0.91%
|
$4,920
$24.44 P/Share
|
|
Mar 05
2021
|
Michael S Simpson SVP, Regulatory Affairs and QA |
SELL
Payment of exercise price or tax liability
|
Direct |
304
-0.89%
|
$7,296
$24.44 P/Share
|
|
Mar 01
2021
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
13,619
-12.99%
|
$340,475
$25.53 P/Share
|
|
Feb 23
2021
|
Franz Peter Barthold VP, Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
704
-5.41%
|
$17,600
$25.41 P/Share
|
|
Feb 23
2021
|
Franz Peter Barthold VP, Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
3,176
+19.63%
|
-
|
|
Feb 23
2021
|
Scott B Capps VP, Clinical Research |
SELL
Payment of exercise price or tax liability
|
Direct |
563
-0.36%
|
$14,075
$25.41 P/Share
|
|
Feb 23
2021
|
Scott B Capps VP, Clinical Research |
BUY
Grant, award, or other acquisition
|
Direct |
3,176
+2.0%
|
-
|
|
Feb 23
2021
|
John E Davis Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
945
-1.14%
|
$23,625
$25.41 P/Share
|
|
Feb 23
2021
|
John E Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,335
+6.06%
|
-
|
|
Feb 23
2021
|
Matthew A Getz VP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
563
-5.59%
|
$14,075
$25.41 P/Share
|
|
Feb 23
2021
|
Matthew A Getz VP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
3,176
+23.96%
|
-
|
|
Feb 23
2021
|
Jean F Holloway SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
990
-1.07%
|
$24,750
$25.41 P/Share
|
|
Feb 23
2021
|
Jean F Holloway SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
5,589
+5.68%
|
-
|
|
Feb 23
2021
|
Amy Horton VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
619
-0.59%
|
$15,475
$25.41 P/Share
|
|
Feb 23
2021
|
Amy Horton VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,493
+3.21%
|
-
|
|
Feb 23
2021
|
David Ashley Lee Executive VP, COO & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,237
-0.42%
|
$30,925
$25.41 P/Share
|
|
Feb 23
2021
|
David Ashley Lee Executive VP, COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
6,987
+2.3%
|
-
|
|
Feb 23
2021
|
James P Mackin President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,383
-1.35%
|
$109,575
$25.41 P/Share
|
|
Feb 23
2021
|
James P Mackin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
28,415
+8.02%
|
-
|
|
Feb 23
2021
|
Dennis B Maier SVP, Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
563
-2.44%
|
$14,075
$25.41 P/Share
|
|
Feb 23
2021
|
Dennis B Maier SVP, Operations |
BUY
Grant, award, or other acquisition
|
Direct |
3,176
+12.09%
|
-
|
|
Feb 23
2021
|
Michael S Simpson SVP, Regulatory Affairs and QA |
SELL
Payment of exercise price or tax liability
|
Direct |
900
-2.58%
|
$22,500
$25.41 P/Share
|
|
Feb 23
2021
|
Michael S Simpson SVP, Regulatory Affairs and QA |
BUY
Grant, award, or other acquisition
|
Direct |
5,081
+12.71%
|
-
|
|
Feb 17
2021
|
Franz Peter Barthold VP, Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
3,548
+26.53%
|
-
|
|
Feb 17
2021
|
Scott B Capps VP, Clinical Research |
BUY
Grant, award, or other acquisition
|
Direct |
3,548
+2.28%
|
-
|
|
Feb 17
2021
|
John E Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,024
+7.22%
|
-
|
|
Feb 17
2021
|
Matthew A Getz VP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
3,725
+35.06%
|
-
|
|
Feb 17
2021
|
Jean F Holloway SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
21,302
+11.25%
|
-
|
|
Feb 17
2021
|
Amy Horton VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,725
+3.52%
|
-
|
|
Feb 17
2021
|
David Ashley Lee Executive VP, COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
7,801
+2.62%
|
-
|
|
Feb 17
2021
|
James P Mackin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
33,125
+10.02%
|
-
|
|
Feb 17
2021
|
Dennis B Maier SVP, Operations |
BUY
Grant, award, or other acquisition
|
Direct |
3,902
+16.38%
|
-
|
|
Feb 17
2021
|
Dennis B Maier SVP, Operations |
SELL
Open market or private sale
|
Direct |
7,197
-15.99%
|
$172,728
$24.68 P/Share
|